Table 2. Distribution pattern of dengue serotype-specific neutralizing antibodies by PRNT.
| Anti-dengue serotype-specific neutralizing antibodies | Frequency N = 120 | Percent (%) | Mean age (95% CI) | Geometric Mean Titer (GMT) (Range)* | |||
|---|---|---|---|---|---|---|---|
| DENV1 | DENV2 | DENV3 | DENV4 | ||||
| Not positive for any antibody | 1 | 0.8 | - | - | - | - | - |
| Monotypic | |||||||
| DENV-1 | 0 | - | - | - | - | - | - |
| DENV-2 | 5 | 4.2 | 27.8 (2.90–52.69) | - | 74.26 (12–255) | - | - |
| DENV-3 | 1 | 0.8 | 35 | - | - | 729.10 | - |
| DENV-4 | 2 | 1.7 | 26 (8.37–43.63) | - | - | - | 154.21 (131.90–180.30) |
| Subtotal | 8 | ||||||
| Multitypic | |||||||
| DENV-1 and DENV-2 | 4 | 3.3 | 19.75 (6.35–33.14) | 87.23 (19.00–267.50) | 27.06 (13.50–59.30) | - | - |
| DENV-2 and DENV-4 | 4 | 3.3 | 33.25 (24.58–41.91) | - | 113.87 (21.60–338.90) | - | 60.28 (19.80–305.30) |
| DENV-2 and DENV-3 | 1 | 0.8 | 35 | - | 280 | 44.3 | - |
| DENV-1, DENV-2 and DENV-3 | 2 | 1.7 | 37.5 (28.68–46.31) | 38.87 (25.70–58.80) | 63.71 (61.70–65.80) | 31.93 (29.90–34.10) | - |
| DENV-1, DENV-2 and DENV-4 | 3 | 2.5 | 20.66 (5.59–35.72) | 31.78 (18.50–66.50) | 57.01 (43.40–73.50) | - | 11.9 (1.40–117.10) |
| DENV-2, DENV-3 and DENV-4 | 14 | 11.7 | 38.57 (28.03–49.10) | - | 227.43 (55.50–1645.50) | 31.31 (10.20–129.20) | 65.35 (10.00–1616.30) |
| DENV-1, DENV-2, DENV-3 and DENV-4 | 83 | 69.2 | 36.31 (32.42–40.19) | 94.48 (10.50–3264.10) | 516.63 (43.00–99167.90) | 167.43 (14.20–2560) | 97.75 (4.90–3264.10) |
| Subtotal | 111 | ||||||
| Total | 119 | ||||||
| Overall GMT (range) | 89.135 (10.50–3264.10) | 334.45 (12.00–99167.90) | 128.60 (10.20–2560) | 88.91 (1.40–1718.60) | |||
*GMT was calculated for sera with PRNT90 titer ≥ 10